AKBA Q1 2022 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$62M+18.0% YoY

Gross Profit

$30M49.2% margin

Operating Income

-$58M-94.8% margin

Net Income

-$62M-101.2% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+7.0%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$535M

Total Liabilities

$509M

Stockholders' Equity

$26M

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$62M	$52M	+18.0%
Gross Profit	$30M	$18M	+71.5%
Operating Income	-$58M	-$65M	+9.9%
Net Income	-$62M	-$70M	+10.3%

Revenue Segments

Product

$41M67%

License Collaboration And Other Revenue

$20M33%